Organigram Global Inc. Common Shares (OGI)

FairStock Score: 73/100 — STEADY

Key Financials

Strengths

• Conservative balance sheet with debt-to-equity of just 0.02, providing financial flexibility
• Revenue growth of 48.7% demonstrates strong top-line momentum
• FairStock composite score of 73/100 places it in the top tier across value, quality, and momentum factors

Concerns

• Weak Piotroski F-Score of 3/9 suggests deteriorating financial quality across multiple dimensions
• Altman Z-Score of -0.3 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Organigram Global Inc. Common Shares is a micro-cap healthcare company valued at $201 million. The business generates $280 million in annual revenue with a 7.1% net margin. From a quality standpoint, Organigram shows weak Piotroski F-Score of 3/9 signaling deteriorating fundamentals and distressed Altman Z-Score of -0.3 warrants caution. On valuation, the stock is attractively valued at 13.1x earnings, with offers a 45% margin of safety vs Graham Number of $3. Growth dynamics show revenue growing at 48.7% and profit growth of 187.0%. Our composite FairStock Score of 73/100 reflects above-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Organigram's 49% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer